Search

Your search keyword '"Rodriguez, M. Alma"' showing total 205 results

Search Constraints

Start Over You searched for: Author "Rodriguez, M. Alma" Remove constraint Author: "Rodriguez, M. Alma"
205 results on '"Rodriguez, M. Alma"'

Search Results

1. NCCN Guidelines® Insights: Survivorship, Version 1.2023.

2. NCCN Guidelines® Insights: Survivorship, Version 1.2022.

3. Survivorship, Version 1.2021.

6. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy

9. Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by 18Fluorodeoxyglucose Positron Emission Tomography

10. Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma

11. Introduction

14. Mantle cell lymphomas

15. The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma

19. Survivorship, Version 2.2020: Featured Updates to the NCCN Guidelines

23. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy

24. Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET–CT-documented First Remission

25. NCCN Guidelines Insights: Survivorship, Version 2.2020

26. Survivorship, Version 2.2019: Featured Updates to the NCCN Guidelines

29. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma

30. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma

31. CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin’s Disease: Associations With Presenting Features and Clinical Outcome

35. NCCN Guidelines Insights: Survivorship, Version 2.2019

36. Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma

37. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

39. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma

40. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma

42. Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

43. Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions

44. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma

45. Survivorship: Healthy Lifestyles, Version 2.2014: Clinical Practice Guidelines in Oncology

46. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma

47. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma

48. NCCN Guidelines Insights: Survivorship, Version 1.2016

49. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

50. Targeting Wnt pathway in mantle cell lymphoma-initiating cells

Catalog

Books, media, physical & digital resources